CA2741302C - Mapkap kinase inhibitor polypeptide for treating or preventing adhesions - Google Patents

Mapkap kinase inhibitor polypeptide for treating or preventing adhesions Download PDF

Info

Publication number
CA2741302C
CA2741302C CA2741302A CA2741302A CA2741302C CA 2741302 C CA2741302 C CA 2741302C CA 2741302 A CA2741302 A CA 2741302A CA 2741302 A CA2741302 A CA 2741302A CA 2741302 C CA2741302 C CA 2741302C
Authority
CA
Canada
Prior art keywords
scar tissue
use according
tissue
existing
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2741302A
Other languages
English (en)
French (fr)
Other versions
CA2741302A1 (en
Inventor
Alyssa Panitch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moerae Matrix Inc
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of CA2741302A1 publication Critical patent/CA2741302A1/en
Application granted granted Critical
Publication of CA2741302C publication Critical patent/CA2741302C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2741302A 2008-10-20 2009-10-20 Mapkap kinase inhibitor polypeptide for treating or preventing adhesions Expired - Fee Related CA2741302C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10683408P 2008-10-20 2008-10-20
US61/106,834 2008-10-20
PCT/US2009/061345 WO2010065206A1 (en) 2008-10-20 2009-10-20 Polypeptide for treating or preventing adhesions

Publications (2)

Publication Number Publication Date
CA2741302A1 CA2741302A1 (en) 2010-06-10
CA2741302C true CA2741302C (en) 2017-02-28

Family

ID=42108870

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2741302A Expired - Fee Related CA2741302C (en) 2008-10-20 2009-10-20 Mapkap kinase inhibitor polypeptide for treating or preventing adhesions

Country Status (11)

Country Link
US (1) US9034815B2 (https=)
EP (1) EP2349310B1 (https=)
JP (1) JP5785085B2 (https=)
KR (2) KR20170001756A (https=)
CN (1) CN102256613B (https=)
AU (1) AU2009322865B2 (https=)
BR (1) BRPI0919759A2 (https=)
CA (1) CA2741302C (https=)
DK (1) DK2349310T3 (https=)
ES (1) ES2507496T3 (https=)
WO (1) WO2010065206A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2617431T3 (en) 2007-01-10 2017-07-10 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and applications therefor
WO2009021137A2 (en) * 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
EP2378875B1 (en) * 2008-12-10 2018-05-30 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9890195B2 (en) * 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20130115256A1 (en) * 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
KR101862291B1 (ko) 2011-04-12 2018-05-29 모레 매트릭스 인코포레이티드 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정을 예방하거나 치료하기 위한 조성물 및 방법
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
ES2991989T3 (es) * 2012-03-23 2024-12-05 Macro Biologics Inc Composiciones y usos de materiales antimicrobianos con propiedades compatibles con tejidos
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
WO2016061145A1 (en) * 2014-10-13 2016-04-21 Symic Biomedical, Inc. Synthetic proteoglycans for preventing tissue adhesion
JP2018501201A (ja) * 2014-11-17 2018-01-18 モイライ マトリックス インコーポレイテッド 異常な線維芽細胞増殖および細胞外マトリックス沈着を特徴とする疾患、状態、またはプロセスを予防または処置するための組成物および方法
WO2016112292A1 (en) * 2015-01-08 2016-07-14 Moerae Matrix, Inc. Formulation of mk2 inhibitor peptides
RU2017135072A (ru) 2015-03-12 2019-04-10 Мори Матрикс, Инк. Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого
US11285189B2 (en) 2017-04-06 2022-03-29 Amicrobe, Inc. Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety
RU2741247C1 (ru) * 2020-10-13 2021-01-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ профилактики перитонеальных спаек женского таза

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) * 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) * 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) * 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
DK172541B1 (da) * 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
DE3682457D1 (de) * 1985-07-30 1991-12-19 Glaxo Group Ltd Geraet zur verabreichung von medikamenten an patienten.
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
JPH07506252A (ja) 1992-04-24 1995-07-13 エス・アール・アイ・インターナシヨナル 真核細胞内でのイン・ビボ相同配列ターゲッティング
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP0733059B1 (en) * 1993-12-09 2000-09-13 Thomas Jefferson University Compounds and methods for site-directed mutations in eukaryotic cells
WO2003084481A2 (en) * 2002-04-01 2003-10-16 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
WO2006071456A2 (en) * 2004-12-02 2006-07-06 The University Of North Carolina At Chapel Hill Inhibition of hsp27 phosphorylation for treatment of blistering disorders
CA2601823C (en) * 2005-04-15 2016-01-12 University Of Arizona Therapeutic peptides for the treatment of metastatic cancer
DK2617431T3 (en) * 2007-01-10 2017-07-10 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and applications therefor
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
WO2008109794A2 (en) * 2007-03-08 2008-09-12 Tufts Medical Center The role of the mk2 pathway in treating fibrosis and scarring
WO2009021137A2 (en) * 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
WO2009123759A2 (en) * 2008-04-02 2009-10-08 Moerae Matrix, Inc. Therapeutic uses of biocompatible biogel compositions

Also Published As

Publication number Publication date
JP2012506442A (ja) 2012-03-15
CN102256613A (zh) 2011-11-23
KR20170001756A (ko) 2017-01-04
BRPI0919759A2 (pt) 2017-03-21
US9034815B2 (en) 2015-05-19
WO2010065206A1 (en) 2010-06-10
EP2349310A1 (en) 2011-08-03
US20100098760A1 (en) 2010-04-22
US20130101671A9 (en) 2013-04-25
ES2507496T3 (es) 2014-10-15
DK2349310T3 (da) 2014-08-11
JP5785085B2 (ja) 2015-09-24
AU2009322865B2 (en) 2013-07-18
AU2009322865A1 (en) 2010-06-10
CN102256613B (zh) 2014-09-10
KR20110095867A (ko) 2011-08-25
CA2741302A1 (en) 2010-06-10
EP2349310B1 (en) 2014-07-23
KR101884616B1 (ko) 2018-08-06
EP2349310A4 (en) 2012-11-21

Similar Documents

Publication Publication Date Title
CA2741302C (en) Mapkap kinase inhibitor polypeptide for treating or preventing adhesions
US9649354B2 (en) Polypeptide inhibitors of HSP27 kinase and uses therfor
US7645733B2 (en) Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
JP2007508823A (ja) 新規な熱ショックタンパク質２０関連ポリペプチドおよびその使用
WO2019198090A1 (en) Treatment of inflammation
HK1161105B (en) Polypeptide for treating or preventing adhesions
HK1161105A (en) Polypeptide for treating or preventing adhesions
CN115279402A (zh) 对ve-ptp磷酸酶的抑制保护肾免于缺血-再灌注损伤
WO2010006635A1 (en) Treatment of inflammatory bowel disease
EP1948216B1 (en) Treatment of acute renal failure with soluble thrombomodulin
JPH05139992A (ja) ヒトａｄｆを含有する臓器保護剤
TWI445543B (zh) 一種用以治療眼部脈絡膜血管新生之醫藥組合物
WO2012030949A2 (en) B2-glycoprotein i peptide inhibitors
JP3569904B2 (ja) 臓器障害治療薬
CA2738757A1 (en) Pharmaceutical compositions and methods of use for the prevention and treatment of hypoxic injury
EP3509613A1 (en) Vasoactive polypeptides for smooth muscle relaxation
KR20160127017A (ko) 폐내 염증의 완화
MXPA98008946A (en) Method of treatment or prevention of the injury caused by isquemia-reperfus

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141020

MKLA Lapsed

Effective date: 20201020